SCG Cell Therapy Announces Launch of Global Manufacturing and R&D Center in Singapore Featuring Proprietary Fully Closed Automated Cell Therapy Production System

Pioneering Fully Closed Automated Cell Therapy Production System, Significantly Expanding Global Capacity and Reducing Costs

SingaporeJuly 21, 2023/PR Newswire/ --SCG SCIENCE (DALIAN) CO., LTD (referred to as “SCG”）Is a biotechnology company focused on developing novel immunotherapies for infectious diseases and their associated cancers. Recently, the company officially opened its cell therapy cGMP manufacturing facility and R&D center at its headquarters in Singapore. With the support of the Singapore Economic Development Board, the new facility fully utilizes and expands SCG’s capabilities in advanced cell therapy.Production System and "Off-the-Shelf"Capabilities in induced Pluripotent Stem Cell (iPSC) technology. The facility will provide cell therapy products to partner hospitals in the Asia-Pacific region, North America, and Europe.

The distinguished guests attending the opening ceremony included: Ms. Low Yen Ling, Minister of State for Trade and Industry of Singapore, Professor Pof Tan Sze Wee, Vice President of Innovation and Enterprise at A*STAR, Mr. Wang Shuli, CEO of SCG SCIENCE, and Professor Ulrike Protzer, founder of SCG SCIENCE.

SCG SCIENCEChief Strategy Officer Christy Ma stated: "Cell therapy has been proven to have the potential to revolutionize the treatment of cancer and many other life-threatening diseases.Treatment Landscape. However, the high manufacturing costs andSignificant capacity constraintsRestrictsPatient Accessibility to Cell Therapy。”

The market price of cell therapies ranges from $373,000 to $475,000 (S$504,000 to S$640,000), depending on the specific drug and indication, and they are in short supply.

InRecentlyA report titled "Bold Goals for U.S. Biotechnology and Biomanufacturing" released by the White House outlines "ambitious goals" related to biotechnology to advance cell therapies.ComprehensiveDevelopment, Expand PatientsAccessibility, andGraduallyReduce manufacturing costs by 10 times^[1]。

The production of cell therapy is typically a complex process. It involves multiple steps, such as handling highly sensitive "live" cells under strictly controlled conditions. SCG utilizes its proprietary closed automated cell therapy production technology,ThoroughlyChanged the traditional open manual process, and has advantages in reducing pollution and risks, improving product consistency and efficiency, increasing scalability, and reducing costs.HugeAdvantages.

Christy added: "Compared with manual production methods, this advanced cellTreatmentThe production system reduces the cleanroom space required for each patient by 80%. It eliminates labor-intensive procedures andProduction CapacityIncreased by 10 times. Overall, it is expected to reduce the manufacturing cost per patient by up to 70%, making cell therapyMost"Treatment options that patients can afford."

In 2021, SCG collaborated with the Cell Therapy Facility of Singapore Health Sciences Authority (HSA-CTF) to validate its proprietary closed automated cell therapy system.ProductionSystem^[2]. The system has been approved by the Health Sciences Authority of Singapore（HSA）And the U.S. Food and Drug Administration（FDA）Clinical Trial Certification.

Ms. Low Yen Ling, Minister of State for Trade and Industry of SingaporeStated: "As part of Singapore's Manufacturing 2030 vision, our goal is to position Singapore as a global hub for advanced manufacturing in terms of business, innovation, and talent. The biotechnology sector is a key component of our strategy. Today, we have a thriving ecosystem comprising both local companies and multinational corporations pursuing their biotech ambitions in Singapore."SCG SCIENCEIt is a promising local startup that, with the support of institutions such as the Health Sciences Authority and the Agency for Science, Technology and Research (A*STAR), has developed the first cell therapy product, SCG101.SCG SCIENCEHeadquartered in Singapore, with teams in China and Germany, providing services covering the entire drug development cycle, including R&D, GMP manufacturing, clinical development, and commercialization.ThiscGMPFacilitiesWill enableSCG SCIENCE"To further expand the business scale. Its development is a good sign for the growth of China's biotechnology industry."

SCG SCIENCEChief Executive OfficerMr. Wang ShuliSaid: "According to Singapore's Advanced Manufacturing Plan, thecGMP FacilityThe启用 isThisRegional Cell Therapy ProductionDevelopment and ProgressAn important milestone. As weA series ofCell Therapy ProductsPipelineGradually推向市场，we期待着进一步扩大我们在Singapore的商业ChemicalProduction capacity to provide high-quality,PossibleBorne byNovelTherapy, meeting the needs of patients in Singapore, the Asia-Pacific region, and even globallyComprehensiveDemand."

Liu YanlingThe lady added: "In addition to cGMPFacilities，SCG SCIENCEA research and development center will also be established to promote the company's cell therapy.CandidateProductEarly StageResearch. The launch of these R&D facilities will support the government's vision and efforts to make Singapore a global innovation hub. At the national level, this work is guided by our Research, Innovation and Enterprise Plan 2025 (RIE2025). I look forward to seeingSCG SCIENCEThrive in our biotechnology ecosystem and drive the development of cell therapy technologies, providing breakthrough 'life-saving' treatments for patients.Medicine’。”